VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 40 filers reported holding VERONA PHARMA PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,273,663 | -22.9% | 4,249,918 | 0.0% | 7.59% | +22.4% |
| Q2 2023 | $89,843,267 | +5.3% | 4,249,918 | 0.0% | 6.20% | +4.7% |
| Q1 2023 | $85,338,353 | +2346294.1% | 4,249,918 | 0.0% | 5.92% | +1313.4% |
| Q4 2022 | $3,637 | -100.0% | 4,249,918 | 0.0% | 0.42% | -91.3% |
| Q3 2022 | $43,434,000 | +277.0% | 4,249,918 | +54.5% | 4.80% | +314.4% |
| Q2 2022 | $11,522,000 | -16.0% | 2,749,918 | 0.0% | 1.16% | +22.4% |
| Q1 2022 | $13,722,000 | -25.7% | 2,749,918 | 0.0% | 0.94% | -15.2% |
| Q4 2021 | $18,479,000 | +22.6% | 2,749,918 | 0.0% | 1.11% | +64.5% |
| Q3 2021 | $15,070,000 | -24.4% | 2,749,918 | -9.8% | 0.68% | -21.6% |
| Q2 2021 | $19,937,000 | -21.8% | 3,048,507 | 0.0% | 0.86% | -3.7% |
| Q1 2021 | $25,486,000 | +19.4% | 3,048,507 | 0.0% | 0.90% | -5.9% |
| Q4 2020 | $21,340,000 | +12.2% | 3,048,507 | 0.0% | 0.95% | -13.4% |
| Q3 2020 | $19,023,000 | +172.3% | 3,048,507 | +104.2% | 1.10% | +119.4% |
| Q2 2020 | $6,987,000 | +13.6% | 1,492,951 | 0.0% | 0.50% | -10.1% |
| Q1 2020 | $6,151,000 | -19.2% | 1,492,951 | 0.0% | 0.56% | -22.0% |
| Q2 2019 | $7,614,000 | -21.5% | 1,492,951 | 0.0% | 0.71% | -26.2% |
| Q1 2019 | $9,704,000 | -27.8% | 1,492,951 | 0.0% | 0.97% | -43.6% |
| Q4 2018 | $13,437,000 | -28.1% | 1,492,951 | 0.0% | 1.72% | -8.8% |
| Q3 2018 | $18,677,000 | +568.9% | 1,492,951 | 0.0% | 1.88% | +422.8% |
| Q2 2018 | $2,792,000 | -90.6% | 1,492,951 | 0.0% | 0.36% | -91.5% |
| Q1 2018 | $29,859,000 | +68.5% | 1,492,951 | 0.0% | 4.23% | +11.4% |
| Q4 2017 | $17,723,000 | -22.7% | 1,492,951 | 0.0% | 3.80% | -18.0% |
| Q3 2017 | $22,917,000 | +179.2% | 1,492,951 | +112.0% | 4.63% | +124.0% |
| Q2 2017 | $8,208,000 | – | 704,225 | – | 2.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |